An interventional study of Autologous Hair Follicle-Derived Secretome and Placebo Control in Androgenic Alopecia, Alopecia and Baldness, sponsored by Acorn Biolabs Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Acorn Biolabs Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 144th largest by enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2025, is one of 93 with no phase, and was the 197th registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Acorn Biolabs Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Acorn Biolabs Inc. has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.
Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.
(SINGLE SITE Study) Androgenic alopecia is a common condition causing hair loss and baldness in both men and women. Approximately 80 million men and women are affected by the condition in the US alone. Although there are a number of products on the market, both over the counter and prescribed, used for androgenic alopecia, they are only somewhat effective to slow the progression.
This trial will evaluate a new approach involving the injection of an autologous product made from the cellular secretions of hair follicles (secretome). Proteonomic analysis has demonstrated that this secretome contains anywhere from 2-22 times the bioactive components of platelet rich plasma (PRP) when compared within the same individual. The hypothesis is that repeat injections of autologous hair follicle-derived secretome will safely and effectively stimulate hair regrowth in men and women suffering from androgenic alopecia.
The trial is a double-blind, randomized, placebo controlled study in 60 patients who are on a stable (>6 months) regimen of minoxidil and 5 alfa-reductase inhibitors. The injections will be delivered at baseline (day 0), 30, 90, 180, 270 and 365 days as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention is autologous hair follicle-derived secretome diluted in saline
Other: Autologous Hair Follicle-Derived Secretome
Placebo control is saline.
Other: Placebo Control
Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.
Also known as: aHFS
The same saline used for diluting the active treatment in will be used as a control.
Target Area Hair Counts (TAHC)
Non-vellus TAHC is the number of non-vellus (terminal) hairs within 1 cm² scalp
Time frame: 180 Days after Baseline
Safety
Incidence rates of treatment-related adverse events compared between the active and placebo arm
Time frame: 180 days from Baseline
Mean Total Hair Density (vellus and non-vellus/terminal)
Mean Total Hair Density (vellus and non-vellus/terminal): measured by Trichoscan device
Time frame: 30, 90, 270 and 365 days
Patient Satisfaction
Patient satisfaction collected using a 5 point Likert scale
Time frame: 30, 90, 270 and 365 days
Hair thickness improvement
Hair thickness improvement measured by Trichoscan device
Time frame: 30, 90, 180, 270 and 365 days
Patient Global Impression of Change (PGIC)
Patient rated improvement in alopecia based on comparison of Baseline to follow-up time point
Time frame: 180 and 365 days
Plan to share: No — This is a proof of concept study on a unique product unlike others so there is no reason to share IPD
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Nov 2026, 13 months.
Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 13 months is above that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2027 → Nov 2026 and completion Sep 2027 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acorn Biolabs Inc.